Scarica l'app Stockscreener
2.11
3.68%
0.07
Precedente Chiudi:
$2.04
Aprire:
$2.03
Volume 24 ore:
469.60K
Relative Volume:
0.09
Capitalizzazione di mercato:
$68.00M
Reddito:
$317.00K
Utile/perdita netta:
$-53.47M
Rapporto P/E:
-1.0933
EPS:
-1.93
Flusso di cassa netto:
$-49.31M
1 W Prestazione:
+9.02%
1M Prestazione:
-2.08%
6M Prestazione:
+37.34%
1 anno Prestazione:
-69.79%
Intervallo 1D:
$2.03
$2.23
Intervallo di 1 settimana:
$1.75
$2.23
Portata 52W:
$1.00
$8.89
Immuneering Corp Stock (IMRX) Company Profile
Nome
Immuneering Corp
Settore
Industria
Telefono
617-500-8080
Indirizzo
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Confronta IMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| IMRX | 2.11 | 68.00M | 317.00K | -53.47M | -49.31M | -1.93 |
| VRTX | 450.39 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.95 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 597.94 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.02 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.45 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-04-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-04-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Iniziato | Mizuho | Neutral |
| 2023-02-03 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Iniziato | Chardan Capital Markets | Buy |
| 2022-04-01 | Iniziato | Oppenheimer | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Immuneering Corp Borsa (IMRX) Ultime notizie
Immuneering Co. (NASDAQ:IMRX) Receives $12.60 Consensus Target Price from Brokerages - MarketBeat
Immuneering Corp. Reports Q3 Loss, Highlights Progress - TipRanks
Immuneering (NASDAQ:IMRX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Short Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 6.7% - MarketBeat
Immuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
IMRX Stock Up on FDA's Orphan Drug Tag for Pancreatic Cancer Drug - Yahoo Finance
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Uncovering the Potential of Immuneering Corp (IMRX) Stock - The InvestChronicle
Nasdaq Insurance Index (INSR) QuotePress Release - The Globe and Mail
FDA grants orphan drug status to Immuneering's cancer treatment - Investing.com
FDA grants orphan drug status to Immuneering's cancer treatment By Investing.com - Investing.com Canada
Financial Health Check: Examining Immuneering Corp (IMRX)’s Key Ratios - The Dwinnex
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer - StockTitan
Here's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Situation - Yahoo Finance
CytomX Therapeutics (NASDAQ:CTMX) & Immuneering (NASDAQ:IMRX) Head to Head Comparison - Defense World
Renaissance Technologies LLC Takes Position in Immuneering Co. (NASDAQ:IMRX) - MarketBeat
IMRX’s Stochastic Averages Dip: Analyzing Immuneering Corp’s Stock Performance - The InvestChronicle
Marshall Wace LLP Makes New Investment in Immuneering Co. (NASDAQ:IMRX) - MarketBeat
The time has not yet come to remove your chips from the table: Immuneering Corp (IMRX) - SETE News
A stock that deserves closer examination: Immuneering Corp (IMRX) - US Post News
Immuneering Corp’s Market Journey: Closing Strong at 2.47, Up 4.22 - The Dwinnex
Immuneering stock maintains Outperform rating on positive prospects - Investing.com
How does Immuneering Corp (IMRX) change from a tortoise to a hare? - SETE News
Understanding the Risks of Investing in Immuneering Corp (IMRX) - Knox Daily
Immuneering Corp (IMRX) Stock: A Year of Decreases and Increases - The InvestChronicle
Immuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immuneering Corp (IMRX)’s stock chart: A technical perspective - US Post News
Ratio Revelations: Immuneering Corp (IMRX)’s Financial Metrics in the Spotlight - The Dwinnex
Biotech Surges Premarket Following Positive Phase 2a Observations - MSN
Immuneering Corp (IMRX) Recovers 161.00% From Low: Sitting In The Catbird Seat? - Stocks Register
Immuneering Corp [IMRX] stock for 1,160,181 USD was sold by Cormorant Asset Management, LP - Knox Daily
You might want to take a look at Immuneering Corp (IMRX) now - SETE News
Immuneering Corp [IMRX] Insider Cormorant Asset Management, LP sells 400,000 Shares - Knox Daily
Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha
Immune Price Drop Is An Entry Opportunity - Top Buzz Times
IMUX’s 2023 Market Saga: Unraveling the Story of Gains and Losses - The InvestChronicle
Analytical Overview: ImmunityBio Inc (IBRX)’s Ratios Tell a Financial Story - The Dwinnex
Market Momentum Report: Immunic Inc (IMUX)’s Negative Close at 1.60 - The Dwinnex
Inflection Point Acquisition Corp. II (NASDAQ:IPXX) Shares Bought by Berkley W R Corp - MarketBeat
Armored car company tires reverse domain name hijacking - Domain Name Wire
Daily Market Movement: Immuneering Corp (IMRX) Sees a -10.59 Decrease, Closing at 2.87 - The Dwinnex
IOH announces stock split to enhance investor participation - Telecompaper EN
Impax Asset Management Group (LON:IPX) Stock Passes Below Fifty Day Moving Average of $383.00 - MarketBeat
Rhumbline Advisers Acquires Shares of 67,184 Immunome, Inc. (NASDAQ:IMNM) - Defense World
ImpediMed Expands U.S. Market Coverage - TipRanks
IDP Education Reports Substantial Shareholder Changes - TipRanks
Analysts review Immunome Inc’s rating - Knox Daily
Immunome (NASDAQ:IMNM) Shares Down 5.6% After Insider Selling - MarketBeat
IMAX Co. (NYSE:IMAX) Shares Sold by Rhumbline Advisers - Defense World
Immuneering Corp Inc. (IMRX) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Ipsen: Parvus AM Europe Ltd falls below 5% of voting rights - Marketscreener.com
Immuneering Corp Azioni (IMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):